What happened with LIMN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Liminatus Pharma, Inc. is a preclinical drug developer focused on IBA101, a humanized antibody targeting CD47 for cancer treatment. Its initial planned use is in advanced solid cancers, including non-small cell lung cancer. The candidate is in late preclinical development, and the company plans to prepare an application seeking permission to begin a Phase 1 clinical trial.
The company has not yet generated revenue and funds operations mainly through equity and debt financing. Its business depends on developing this single candidate into a commercial product. The underlying CD47 asset is licensed from InnoBation Bio Co. Ltd.; Liminatus holds exclusive worldwide development and commercialization rights within the licensed field and is responsible for development costs.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Liminatus hinges on funding and clinically validating its sole CD47 drug candidate, whose exclusive worldwide rights it licenses from InnoBation Bio.
Gilead Sciences’ setbacks with magrolimab give Liminatus investors a direct safety and efficacy benchmark for its own CD47 cancer antibody. Magrolimab’s red-blood-cell binding and associated anemia highlight what Liminatus must distinguish clinically; its reported lack of red-blood-cell binding remains a preclinical finding.
AstraZeneca sells the lung-cancer medicine Liminatus plans to combine with its CD47 antibody: durvalumab, marketed as Imfinzi. For Liminatus investors, news about that medicine in non-small cell lung cancer is relevant to the planned combination.
Merck sells pembrolizumab for lung cancer, making it relevant to Liminatus’s plan to test its CD47 antibody with that medicine. Watch pembrolizumab developments in non-small cell lung cancer, the setting of Liminatus’s planned combination.
Inhibrx Biosciences overlaps Liminatus’s planned lung-cancer trials by testing INBRX-106 alone and with pembrolizumab in non-small cell lung cancer. Its INBRX-106 combination results are the relevant comparison; Inhibrx earns revenue from licensing and grants, not commercial sales of approved medicines.
Innate Pharma’s monalizumab program with AstraZeneca overlaps Liminatus’s planned lung-cancer combination treatment: both pair an immunotherapy with durvalumab. Watch progress on monalizumab with durvalumab as a competing approach in that treatment setting.
Compugen competes with Liminatus in developing antibodies to overcome tumors’ ability to evade the immune system, and receives payments from drug-company partners for licensed programs. Watch rilvegostomig, its antibody targeting both PD-1 and TIGIT that AstraZeneca develops, as an alternative to Liminatus’s CD47-based approach.
Agenus competes with Liminatus’s planned CD47-based combinations by developing antibody combinations for solid cancers. Its botensilimab–balstilimab treatment began generating revenue through authorized access programs in the second half of 2025, but that access is not marketing approval.
Gilead Sciences Inc earningsGILD
Gilead Sciences’ report may bring updates on the safety and efficacy of magrolimab, another CD47 antibody, giving readers a benchmark for Liminatus’s IBA101 without proving how IBA101 will perform.
Look for clinical safety information, especially red-blood-cell binding and anemia, alongside any efficacy evidence for magrolimab. Fewer safety concerns and a clear efficacy signal would make the same-target benchmark more reassuring, but would not establish IBA101’s safety or efficacy; persistent anemia or weak efficacy would underscore the clinical hurdles CD47 antibodies face.
Merck & Co., Inc. earningsMRK
Merck’s report may show how pembrolizumab is progressing in lung cancer, the setting for Liminatus’s planned IBA101 combination with the drug.
Look for developments involving pembrolizumab in non-small cell lung cancer. A solid clinical footing for the drug in this setting would give Liminatus’s planned combination a clearer rationale, but would not show that the two drugs work together; setbacks would weaken the context for this particular combination.
AstraZeneca PLC earningsAZN
AstraZeneca’s report may show how durvalumab is progressing in non-small cell lung cancer, the setting for another planned Liminatus IBA101 combination.
Look for developments involving durvalumab in non-small cell lung cancer. A solid clinical footing for the drug in this setting would give Liminatus’s planned combination a clearer rationale, but would not show that the two drugs work together; setbacks would weaken the context for this option.
Agenus Inc. earningsAGEN
Agenus’s report may show progress for its solid-tumor antibody combination and revenue from authorized access programs, offering a comparison with another antibody-combination approach to cancer.
Read clinical progress for botensilimab–balstilimab alongside revenue from authorized access programs. Continued progress and rising program revenue would show patients are receiving the treatment through those programs, not that it has marketing approval or is commercially competing with IBA101; weaker progress or revenue would offer less evidence of traction for this antibody-combination approach.
